Investing.com -- Adicet Bio shares jumped 6.4% premarket after the company announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its investigational therapy ADI-001 for the treatment of systemic sclerosis (SSc).
ADI-001 is a CAR T cell therapy that targets CD20 to treat autoimmune diseases.
Fast Track Designation is intended to accelerate the development and regulatory review of drugs aimed at treating serious conditions with unmet medical needs.
The designation provides Adicet Bio with several potential advantages, including more frequent FDA interactions, eligibility for priority review, and the possibility of accelerated approval if clinical data supports it.
This milestone strengthens Adicet Bio’s position in the cell therapy space, particularly in autoimmune diseases and cancer, where the company is focused on developing novel gamma delta T cell-based treatments.
The stock’s premarket jump reflects investor optimism about the regulatory progress of ADI-001 and its potential to address systemic sclerosis.
Related Articles
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001
Target and Warby Parker team up for in-store eyewear shops
Microsoft urges Trump to overhaul Biden's last AI chip export curbs
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.